Adjuvatis
Entity

  • Adjuvatis

    Created in 2013
  • BETA

    Up & running (A)
    Existing signals show a regular activity

  • Social networks

    67 695

  • Activities

    deeptech biotech

  • Technologies

    Synthetic Biology

  • Entity types

    Startup

  • Location

    60 Av. Rockefeller, 69008 Lyon, France

    Lyon

    France

  • Employees

    Scale: 2-10

    Estimated: 4

  • SIREN

    799085196

  • Engaged corporates

    2
    0 2

  • Added in Motherbase

    1 year, 3 months ago
Description
  • Value proposition

    Built around safe-by-design concept, Adjuvatis is committed for innovative formulations to improve pharmaceuticals

    Adjuvatis, a French startup in biotechnology, develops innovative safe-by-design delivery systems to help laboratories and pharmaceutical companies in vaccine formulation as adjuvants and in drug delivery as vectors for oncology, dermatology, infections, etc.
    Our first technology, called i-Particles®, is based on 200 nm-diameter particles composed of poly-lactic acid only (any surfactant and solvents) for formulation of hydrophobic molecules in the particle core and surface functionalization of peptides. Our second technology, i-LipoP®, consists in i-Particles® covered by lipidic bilayers at their surface for vectorization of nucleic acids and peptides.

    Drug Delivery, Formulation, Characterization of particles, and Vaccine Adjuvant

  • Original language

    Built around safe-by-design concept, Adjuvatis is committed for innovative formulations to improve pharmaceuticals

    Adjuvatis, a French start up in Biotechnology created in December 2013, develops a new eco-compatible delivery system initially designed by researchers from a joint unit between the public institution CNRS and the private company bioMerieux. Ten years of research development and evaluation at international level has allowed the creation of Adjuvatis.
    Adjuvatis is specialized in the development, manufacturing and formulation of around 200 nm biodegradable particles based on poly(lactic acid), called i-Particles® and produced by an eco-compatible method, surfactant free. Our company’s key objective is to share the i-Particles® technology and help researchers, biopharmaceutical & diagnostic companies in:
    - the development of new adjuvants for safer and more efficient vaccines (animal & human vaccines) - VACCINE PLATFORM
    - the generation of new antibodies (polyclonal and monoclonal) using hard to use antigens formulated on our particles - ANTIBODY GENERATION
    - offering new drug delivery solutions by a shear-free encapsulation method - DELIVERY PLATFORM

    Our particles were evaluated as adjuvant especially for vaccine development (animal & human vaccines), and as drug delivery system in oncology, dermatology, infections, etc.

Corporate interactions BETA
Corporate TypeTweets Articles
Lyonbiopôle Auvergne-Rhône-Alpes
Lyonbiopôle Auvergne-Rhône-Alpes
Public business cluster, Biotechnology, French Cluster, Biotechnology Research
Lyonbiopôle Auvergne-Rhône-Alpes
Public business cluster, Biotechnology, French Cluster, Biotechnology Research 		Other

28 Feb 2023


Région Auvergne-Rhône-Alpes
Région Auvergne-Rhône-Alpes
National and local authorities, Government Administration
Région Auvergne-Rhône-Alpes
National and local authorities, Government Administration 		Other

28 Feb 2023


Similar entities
Last news
Show all articles
Social network dynamics